— Obalon Therapeutics (NASDAQ: OBLN) reported a net loss of $0.61 per share for the third quarter of 2019, vs. $2.14 per share loss expected.
— Third-quarter net loss was $3.7 million, compared to a loss of $6.7 million a year earlier
— Revenue decreased to $0.3 million from $3.0 million in the third quarter of 2018, vs. $1.2 million loss expected
— Cost of revenue was $0.4 million, down from $1.4 million in the same period of last year
— Research and development expense declined sharply to $1.2 million from $2.4 million last year
— Opened the first company-owned retail treatment center, the Obalon Center for Weight Loss
— Raised $16.6 million in gross proceeds from an equity offering
— Promoted William Plovanic to President and CEO; promoted Nooshin Hussainy to CFO
Most Popular
Hormel (HRL) expects earnings pressure to continue into Q1 2026
Shares of Hormel Foods Corporation (NYSE: HRL) gained over 3% on Thursday. The company delivered mixed results for the fourth quarter of 2025, as earnings came ahead of expectations while
Key metrics from Kroger’s (KR) Q3 2025 earnings results
The Kroger Co. (NYSE: KR) reported its third quarter 2025 earnings results today. Total company sales rose to $33.9 billion from $33.6 billion in the same period last year. Identical
Dollar General (DG) Q3 2025 Earnings: Key financials and quarterly highlights
Dollar General Corporation (NYSE: DG) reported its third quarter 2025 earnings results today. Net sales increased 4.6% year-over-year to $10.65 billion. Same-store sales increased 2.5%. Net income was $282.7 million, or
